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Abstract
Immunization of healthy volunteers with chloroquine ChemoProphylaxis and Sporozoites (CPS-CQ) efficiently and
reproducibly induces dose-dependent and long-lasting protection against homologous Plasmodium falciparum challenge.
Here, we studied whether chloroquine can be replaced by mefloquine, which is the only other licensed anti-malarial
chemoprophylactic drug that does not affect pre-erythrocytic stages, exposure to which is considered essential for
induction of protection by CPS immunization. In a double blind randomized controlled clinical trial, volunteers under either
chloroquine prophylaxis (CPS-CQ, n = 5) or mefloquine prophylaxis (CPS-MQ, n = 10) received three sub-optimal CPS
immunizations by bites from eight P. falciparum infected mosquitoes each, at monthly intervals. Four control volunteers
received mefloquine prophylaxis and bites from uninfected mosquitoes. CPS-MQ immunization is safe and equally potent
compared to CPS-CQ inducing protection in 7/10 (70%) versus 3/5 (60%) volunteers, respectively. Furthermore, specific
antibody levels and cellular immune memory responses were comparable between both groups. We therefore conclude
that mefloquine and chloroquine are equally effective in CPS-induced immune responses and protection.
Trial Registration: ClinicalTrials.gov NCT01422954
Citation: Bijker EM, Schats R, Obiero JM, Behet MC, van Gemert G-J, et al. (2014) Sporozoite Immunization of Human Volunteers under Mefloquine Prophylaxis Is
Safe, Immunogenic and Protective: A Double-Blind Randomized Controlled Clinical Trial. PLoS ONE 9(11): e112910. doi:10.1371/journal.pone.0112910
Editor: Steffen Borrmann, Kenya Medical Research Institute - Wellcome Trust Research Programme, Kenya
Received July 10, 2014; Accepted October 14, 2014; Published November 14, 2014
Copyright:  2014 Bijker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This trial was funded by The Netherlands Organisation for Health Research and Development (ZonMw, project 95110086) and the Dioraphte
foundation (project 12010100). AS received an EMBO long-term fellowship. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: Robert.Sauerwein@radboudumc.nl
. These authors contributed equally to this work.
Introduction
Malaria remains one of the most important infectious diseases
worldwide and still causes approximately 207 million cases and
627,000 deaths every year [1]. Anti-disease immunity against
malaria is not easily induced: in endemic areas this takes many
years of repeated exposure to develop [2], and sterile protection
against infection does not seem to be induced at all [3]. Also
candidate vaccines have shown only limited protective efficacy so
far [4,5]. Novel vaccines and drugs can be tested for efficacy at an
early stage of clinical development in Controlled Human Malaria
Infection (CHMI) studies, exposing a small number of healthy
volunteers to Plasmodium falciparum by bites from infected
Anopheles mosquitoes. Immunization of healthy volunteers under
chloroquine ChemoProphylaxis with Sporozoites (CPS-CQ im-
munization) efficiently, reproducibly and dose-dependently induc-
es protection against homologous CHMI [6,7], shown in a subset
of volunteers to last for more than 2 years [8]. CPS-CQ
immunization requires exposure to bites from only a total of 30–
45 P. falciparum infected mosquitoes to induce 89–95%
protection [6,7,9]. In contrast, protection by immunization with
radiation-attenuated sporozoites (RAS) requires a minimum of
1000 infected mosquito bites [10], or intravenous injection of five
times 135,000 cryopreserved sporozoites [11].
The unprecedented efficiency of the CPS immunization regime
may relate to its design: in contrast to RAS, CPS immunization
allows full liver stage development and exposure to early blood-
stages. Moreover, chloroquine is known for its immunomodulatory
capacities [12–14] that may play a role in induction of protection,
which is mediated by pre-erythrocytic immunity [9] including
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antibodies directed against sporozoites [15–17], and likely T cells
targeting liver-stages [7]. Next to chloroquine, mefloquine (MQ) is
the only licensed drug for chemoprophylaxis that does not affect
pre-erythrocytic stage development [18]. We therefore aimed to
assess whether chloroquine could be replaced by mefloquine for
CPS immunization. In a double blind randomized controlled
clinical trial we assessed safety, immunogenicity and protection
against challenge for CPS-MQ compared to CPS-CQ.
Methods
Study subjects
Healthy subjects between 18 and 35 years old with no history of
malaria were screened for eligibility based on medical and family
history, physical examination and standard hematological and
biochemical measurements. Urine toxicology screening was
negative in all included subjects; none of the subjects were
pregnant or lactating. Serological analysis for HIV, hepatitis B,
hepatitis C and P. falciparum asexual blood-stages was negative in
all subjects. All subjects had an estimated 10-year risk smaller than
5% of developing a cardiac event as estimated by the Systematic
Coronary Evaluation System adjusted for the Dutch population
[19]. None of the subjects had travelled to a malaria-endemic area
during or within 6 months prior to the start of the study. All
subjects provided written informed consent before screening. The
Central Committee for Research Involving Human Subjects of
The Netherlands approved the study (NL 37563.058.11). Inves-
tigators complied with the Declaration of Helsinki and Good
Clinical Practice including monitoring of data. This trial is
registered at ClinicalTrials.gov, identifier NCT01422954. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information (Checklist S1 and Protocol
S1).
Study design and procedures
This single center, double blind randomized controlled trial was
conducted at Leiden University Medical Center (Leiden, the
Netherlands) from April 2012 until April 2013 (Figure 1). Twenty
subjects were randomly divided into three groups by an
independent investigator using a computer-generated random-
number table. Subjects, investigators and primary outcome
assessors were blinded to the allocation. Subjects in the CPS-CQ
group (n = 5) received a standard prophylactic regimen of
chloroquine consisting of a loading dose of 300 mg on the first
and fourth day and subsequently 300 mg once a week for 12
weeks. Subjects in the CPS-MQ group (n= 10) and the control
group (n= 5) received mefloquine prophylaxis starting with a
loading split dose regimen to limit potential side-effects: 125 mg
twice per week for a duration of 3 weeks and subsequently 250 mg
once a week for 12 weeks. Chloroquine and mefloquine were
administered as capsules, indistinguishable from each other.
During this period all subjects were exposed to the bites of 8
Anopheles mosquitoes three times at monthly intervals, starting 22
days after start of mefloquine prophylaxis and 8 days after start of
chloroquine prophylaxis. Volunteers in the CPS-CQ and CPS-
MQ groups received bites from mosquitoes infected with the P.
falciparum NF54 strain, control subjects received bites from
uninfected mosquitoes. The immunization dose was based on our
previous dose-de-escalation trial [7] and aimed to establish partial
protection in the CPS-CQ group in order to enable detection of
either improved or reduced protection in the CPS-MQ group.
Sample sizes were calculated based on the expected difference of 4
days in prepatent period between the CPS-CQ and CPS-MQ
groups, a standard deviation of 1.6 and 2.3 days respectively, an a
of 5% and a power of 0.90. This calculation resulted in a CPS-CQ
group of 4 and a CPS-MQ group of 8 subjects. To account for
possible dropouts based on (perceived) side effects we included one
and two extra volunteers in the CPS-CQ and CPS-MQ groups
respectively. The control group was included as infectivity control
for the challenge infection.
On days 6 to 10 after each immunization by mosquito exposure,
all subjects were followed on an outpatient basis and peripheral
blood was drawn for blood smears, standard hematological
measurements, cardiovascular markers and retrospective qPCR.
Twenty weeks after the last immunization, sixteen weeks after
discontinuation of prophylaxis, all subjects were challenged by the
bites of five mosquitoes infected with the homologous NF54 P.
falciparum strain, according to previous protocols [20]. After this
challenge-infection, all subjects were checked twice daily on an
outpatient basis from day 5 up until day 15 and once daily from
day 16 up until day 21 for symptoms and signs of malaria. Thick
blood smears for parasite detection were made during each of
these visits after challenge, hematological and cardiovascular
markers were assessed daily. As soon as parasites were detected by
thick smear, subjects were treated with a standard curative
regimen of 1000 mg atovaquone and 400 mg proguanil once daily
for three days according to Dutch national malaria treatment
guidelines. If subjects remained thick smear negative, they were
presumptively treated with the same curative regimen on day 21
after challenge infection. All subjects were followed closely for 3
days after initiation of treatment and complete cure was confirmed
by two negative blood smears after the last treatment dose.
Chloroquine and mefloquine levels were measured retrospectively
in citrate-plasma from the day before challenge by liquid
chromatography (detection limit for both chloroquine and
mefloquine: 5 mg/L) [21].
Anopheles stephensi mosquitoes for immunizations and chal-
lenge-infection were reared according to standard procedures at
the insectary of the Radboud university medical center. Infected
mosquitoes were obtained by feeding on NF54 gametocytes, a
chloroquine- and mefloquine-sensitive P. falciparum strain, as
described previously [22]. After exposure of volunteers, all blood-
engorged mosquitoes were dissected to confirm the presence of
sporozoites. If necessary, feeding sessions were repeated until the
predefined number of infected or uninfected mosquitoes had fed.
Endpoints
The primary endpoint was prepatent period, defined as the time
between challenge and first positive thick blood smear. Secondary
endpoints were parasitemia and kinetics of parasitemia as
measured by qPCR, adverse events and immune responses.
Detection of parasites by thick smear
Blood was sampled twice daily from day 5 until day 15 and once
daily from day 16 up until day 21 after challenge and thick smears
were prepared and read as described previously [9]. In short,
approximately 0.5 ml of blood were assessed by microscopy and
the smear was considered positive if two unambiguous parasites
were seen.
Quantification of parasitemia by qPCR
Retrospectively, parasitemia was quantified by real-time quan-
titative PCR (qPCR) on samples from day 6 until day 10 after each
immunization and from day 5 until day 21 after challenge as
described previously [23], with some modifications. Briefly, 5 ml
Zap-Oglobin II Lytic Reagent (Beckman Coulter) was added to
0.5 ml of EDTA blood, after which the samples were mixed and
stored at 280uC. After thawing, samples were spiked with the
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extraction control Phocine Herpes Virus (PhHV) and DNA was
extracted with a MagnaPure LC isolation instrument. Isolated
DNA was resuspended in 50 ml H2O, and 5 ml was used as
template. For the detection of P. falciparum, the primers as
described earlier [23] and the TaqMan MGB probe AAC AAT
TGG AGG GCA AG-FAM were used. For quantification of
PhHV the primers GGGCGAATCACAGATTGAATC, GCG-
GTTCCAAACGTACCAA and the probe Cy5-
TTTTTATGTGTCCGCCACCATCTGGATC were used. The
sensitivity of qPCR was 35 parasites/ml of whole blood.
Adverse events and safety lab
Adverse events (AEs) were recorded as following: mild events
(easily tolerated), moderate events (interfering with normal
activity), or severe events (preventing normal activity). Fever was
recorded as grade 1 (.37?5uC–38?0uC), grade 2 (.38?0uC–
39?0uC) or grade 3 (.39?0uC). Platelet and lymphocyte counts
were determined in EDTA-anti-coagulated blood with the Sysmex
XE-2100 (Sysmex Europe GmbH, Norderstedt, Germany). D-
dimer concentrations were assessed in citrate plasma by STA-R
Evolution (Roche Diagnostics, Almere, The Netherlands).
Immunological analyses
In order to assess cellular immune memory responses,
peripheral blood mononuclear cell (PBMC) re-stimulation assays
were performed as described previously [7]. PBMCs were
collected, frozen in fetal calf serum containing 10% dimethylsulf-
oxide, and stored in vapor phase nitrogen before initiation of
prophylaxis (baseline; B) and one day before the challenge
infection (C-1).
After thawing, PBMCs were re-exposed in vitro to P.
falciparum-infected red blood cells (PfRBC) and incubated for
24 hours at 37uC in the presence of a fluorochrome-labeled
antibody against CD107a. Uninfected red blood cells (uRBCs)
were used as a negative control. During the last 4 hours of
incubation, 10 mg/ml Brefeldin A and 2 mM Monensin were
added, allowing cytokines to accumulate within the cells. As a
positive control, 50 ng/ml PMA and 1 mg/ml ionomycin were
added for the last four hours of incubation. After 24 h stimulation,
cells were further stained with a viability marker and fluoro-
chrome-labeled antibodies against CD3, CD4, CD8, CD56, cd-T
cell receptor, IFNc and granzyme B (Table S1 [7]). For each
volunteer, cells from all time points were tested in a single
experiment: thawed and stimulated on the same day and stained
the following day. Samples were acquired on a 9-color Cyan ADP
(Beckman Coulter) and data analysis was performed using FlowJo
software (version 9.6.4; Tree Star). A representative example
showing the full gating strategy is shown in Figure S1. Gating of
cytokine-positive cells was performed in a standardized way by
multiplying a fixed factor with the 75 percentile of the geometric
Mean Fluorescent Intensity (MFI) of cytokine negative PBMCs for
each volunteer, time point and stimulus. Responses to uRBC were
subtracted from the response to PfRBC for each volunteer on
every time point.
Plasma for the assessment of malaria-specific antibodies was
collected and stored at baseline (B), 27 days after the first
immunization (I1; one day before the second immunization), 27
days after the second immunization (I2; one day before the third
immunization), and one day before the challenge infection (C-1).
Antibody titers were assessed as described previously [17]. In
Figure 1. Study flow diagram. Thirty-six subjects were screened for eligibility, of whom twenty were included in the trial and randomized over
three groups. One control subject was excluded after initiation of chemoprophylaxis but before the first immunization because of an unexpected visit
to a malaria-endemic area during the study period. In a double-blind fashion, fifteen subjects received either CPS-CQ or CPS-MQ immunization and
four control subjects received bites from uninfected mosquitoes and mefloquine prophylaxis. Subjects received a challenge infection by bites of five
infected mosquitoes sixteen weeks after discontinuation of prophylaxis.
doi:10.1371/journal.pone.0112910.g001
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summary, serially diluted citrate plasma was used to perform
standardized enzyme-linked immunosorbent assay (ELISA) in
NUNC Maxisorp plates (Thermo Scientific) coated with 1 mg/ml
circumsporozoite protein (CSP), liver-stage antigen-1 (LSA-1) or
merozoite surface protein-1 (MSP-1) antigen, diluted in PBS.
Bound IgG was detected using horseradish peroxidase (HRP)
conjugated anti-human IgG) (Thermo Scientific, 1/60000) and
Tetramethylbenzidine (all Mabtech). Spectrophotometrical absor-
bance was measured at 450 nm. OD values were converted into
AUs by four-parameter logistic curve fit using Auditable Data
Analysis and Management System for ELISA (ADAMSEL-v1.1,
http://www.malariaresearch.eu/content/software; accessed 27
October 2014). Levels of antibodies were calculated in relation
to a pool of 100 sera from adults living in a highly endemic area in
Tanzania (HIT serum [24]), which was defined to contain 100
arbitrary units (AU) of IgG directed against each antigen.
Statistical analyses
The proportion of protected subjects in the CPS-CQ versus
CPS-MQ group was tested with the Fisher’s exact test using
Graphpad Quickcalcs online and the 95% confidence interval (CI)
of protection for each group was calculated by modified Wald
Method [25]. Further statistical analyses were performed with
GraphPad Prism 5. Differences in prepatent period and time from
qPCR positivity until thick smear positivity were tested by Mann
Whitney test. Antibody levels are shown as individual titers with
medians and differences between time points were analyzed by
Friedman test with Dunn’s multiple comparison post-hoc test.
Induction of cellular immune responses was tested for CPS-CQ
and CPS-MQ groups separately by Wilcoxon matched-pairs
signed rank test (B versus C-1). A p-value of ,0.05 was considered
statistically significant. Analyses of parasitemia were performed on
log transformed data, the geometric mean peak parasitemia after
each immunization was calculated using the maximum parasit-
emia for each subject.
Results
Safety of CPS-CQ and CPS-MQ immunization
Twenty out of 36 screened subjects (median age 21 years; range
18–25) were included in the study (Figure 1). One control subject
was excluded between start of prophylaxis and the first immuni-
Figure 2. Parasitemia during CPS immunization. Parasitemia was determined retrospectively, once daily from day 6 until day 10 after each
immunization, by real-time quantitative PCR (qPCR). Each line represents an individual subject from the CPS-MQ (dashed blue lines) or CPS-CQ group
(red lines). The number of subjects with a positive qPCR/total number of volunteers in the CPS-MQ (blue) and CPS-CQ (red) groups after each
immunization are shown above the graph. Values shown as 17.5 on the log-scale were negative (i.e. half the detection limit of the qPCR: 35 parasites/
ml).
doi:10.1371/journal.pone.0112910.g002
Figure 3. Adverse events during CPS immunization. Percentage
of volunteers in each group experiencing possibly or probably related
AE after the first (I), second (II) and third (III) immunization. AEs were
evaluated at each visit and graded for severity as described in the
methods paragraph: mild (light grey), moderate (dark grey) and severe
(black). Only the highest intensity per subject is listed. No Serious
Adverse Events occurred.
doi:10.1371/journal.pone.0112910.g003
Sporozoite Immunization of Human Volunteers
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zation because of an unexpected intermittent visit to a malaria-
endemic area. Thick blood smears performed from day 6 up until
day 10 after each immunization remained negative in all
volunteers. As determined retrospectively by qPCR, 2/5 subjects
in the CPS-CQ group and 7/10 subjects in the CPS-MQ group
showed sub-microscopic parasitemia after the first immunization
(geometric mean peak parasitemia for positive subjects: 948
parasites/ml [range 228–3938] and 256 parasites/ml [range 48–
1559] respectively, Figure 2). After the second immunization,
four CPS-MQ subjects showed sub-microscopic parasitemia
(geometric mean peak parasitemia for positive subjects 104
parasites/ml [range 48–223]), while none of the CPS-CQ subjects
showed parasitemia. After the third immunization, only one CPS-
MQ subject showed parasitemia by qPCR (peak parasitemia 1059
Pf/ml).
After the first immunization, all subjects (5/5) in the CPS-CQ
group and almost all CPS-MQ subjects (8/9) experienced possibly
or probably related AEs. One subject in each group had a grade 3
AE (headache and vomiting, respectively). Two control volunteers
reported mild AEs (Figure 3 and Table S2). After the second
immunization, two CPS-CQ volunteers and six volunteers in the
CPS-MQ group had mild AEs. Two control subjects experienced
moderate and severe headache, respectively. After the third
immunization, one volunteer in the CPS-CQ group and four CPS-
MQ volunteers had AEs; one control subject experienced mild
AEs (Figure 3 and Table S2). One CPS-CQ subject reported
moderate sleeping problems while taking chloroquine prophylaxis.
One control subject had moderate problems with initiation of
sleep and another control subject experienced vivid dreams under
mefloquine prophylaxis. Other than mild to moderate dizziness
and sleep related AEs, which all resolved after chemoprophylaxis
was stopped, no neuropsychiatric AEs occurred. No serious
adverse events occurred.
During immunization, one subject each in the CPS-CQ, CPS-
MQ and control groups showed platelet counts below the lower
limit of normal (1506109/L); lowest values 1056109/L,
1166109/L and 1316109/L, respectively. Three, five and two
subjects from the CPS-CQ, CPS-MQ and control groups
respectively, showed leukocyte counts below the lower limit of
normal (46109/L); mean lowest value during immunization
period: 3.86109/L [SD 1.2], 4.06109/L [SD 1.1] and 4.26109/
L [SD 0.7] respectively. No subject developed leukocyte counts
lower than 2.06109/L. One volunteer in each group showed
leukocyte counts above the upper limit of normal (106109/L;
highest values 10.86109/L, 13.86109/L and 10.16109/L respec-
tively). After the first immunization, 3/5 CPS-CQ subjects, 7/10
in the CPS-MQ group and none in the control group developed
elevated d-dimer levels (.500 ng/ml). After the second immuni-
zation, six CPS-MQ subjects but none in the CPS-CQ or control
groups showed elevated d-dimer levels. After the third immuni-
zation, three CPS-MQ subjects showed elevated d-dimer levels,
while none of the subjects in the other groups did.
Protection against challenge infection
In the CPS-CQ group 3/5 subjects and in the CPS-MQ group
7/10 volunteers were protected against challenge infection
(Fisher’s exact test p = 1.0). All control subjects became thick
smear positive (median day 8.5, range 7–12, p= 0.03 versus CPS-
immunized subjects; Table 1). None of the protected subjects
showed parasitemia by qPCR at any time point during follow-up
(Figure 4). The median prepatent period was not significantly
different between the CPS-CQ and CPS-MQ groups, neither
when protected subjects were arbitrarily set at a prepatent period
of 21 days (p = 1.00), nor when comparing unprotected subjects
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only (p = 0.1). The median chloroquine plasma concentration on
the day before challenge infection was 9 mg/L (range 7–10) in the
CPS-CQ group, and the median mefloquine concentration was
24 mg/L (range 5–116) in the mefloquine groups.
Immunogenicity of CPS-CQ and CPS-MQ
Antibodies against the pre-erythrocytic antigens CSP and LSA-
1 and the cross-stage antigen MSP-1 were assessed by ELISA.
Antibodies against CSP were induced in both CPS-CQ and CPS-
MQ immunized volunteers (p,0.05 and p,0.01 respectively, on
C-1; Figure 5A and 5B), but not significantly higher in
protected compared to unprotected subjects (p = 0.88 and
p= 0.48 respectively). Antibodies against LSA-1 were only
significantly induced in CPS-MQ immunized volunteers on I2
(p,0.001; Figure 5C and 5D), although not higher in
protected subjects (p = 0.39). Anti-MSP-1 antibodies by CPS
immunization were not statistically significant increased in either
group (Figure 5E and 5F).
IFNc production by both adaptive and innate cell subsets in
response to in vitro P. falciparum re-stimulation was induced by
both CPS-CQ and CPS-MQ (Figure S2), without a clear
quantitative or qualitative difference between the study groups.
Next, CD107a expression by CD4 T cells and granzyme B
production by CD8 T cells, both associated with protection in a
previous CPS-CQ trial [7], were assessed by flow cytometry. Four
out of 5 CPS-CQ and 8/10 CPS-MQ immunized subjects showed
induction of CD107a expression by CD4 T cells upon in vitro re-
stimulation after immunization (Figure 6A and 6B). Although
volunteer numbers were too low to reach statistical significance,
the magnitude of this response appeared to be associated with
protection for CPS-CQ (Figure 6A), while for CPS-MQ it was
not (Figure 6B). Granzyme B production by CD8 T cells was not
significantly induced in either CPS-CQ or CPS-MQ group, nor
was it associated with protection (Figure 6C and 6D).
After challenge, MSP-1 specific antibodies were boosted in all
unprotected volunteers (fold change median 20.4 (range 7.1–33.6),
76.0 (5.7–106.3) and 7.7 (2.9–15.3) for CPS-CQ, CPS-MQ and
control groups respectively). None of the protected subjects
showed an increase in MSP-1 antibody levels on C+35 compared
to C-1 (median fold change 1.0 (range 1.0–1.3) and 1.0 (0.6–2.4)
for CPS-CQ and CPS-MQ groups, respectively).
Discussion
Immunization of healthy volunteers with P. falciparum
sporozoites while taking mefloquine prophylaxis is safe, induces
both humoral and cellular immune responses and protects against
homologous malaria challenge.
Although most volunteers experienced AEs after the first
immunization, their frequency declined after subsequent
immunizations in line with a reducing number of volunteers
developing parasitemia. The majority of AEs was mild, with
only 10–20% of subjects experiencing a grade 3 AEs after each
immunization. In general, the reported neurologic and psychi-
atric side effects of mefloquine are a major concern limiting its
acceptability and clinical application. In this study, mild to
moderate dizziness and sleep-related complaints occurred in a
small number of subjects in both chloroquine and mefloquine
groups. Although this study was not powered to detect
differences in AEs, frequency of neuropsychiatric AEs did not
appear to differ between both drugs. This is in line with most
reports in literature comparing AEs of mefloquine or chloro-
quine (with or without proguanil) for chemo-prophylactic use
[26–29] although one study found more neuropsychiatric AEs in
subjects taking mefloquine by retrospective questionnaire [30].
Taking the small sample size into consideration, both CPS-CQ
Figure 4. Parasitemia after challenge infection. Parasitemia was assessed retrospectively by real-time quantitative PCR (qPCR) twice daily from
day 5 until day 15 and once daily up until day 21 after challenge. Each line represents an individual subject. Red lines represent CPS-CQ immunized
volunteers (n = 5), dashed blue lines CPS-MQ immunized subjects (n = 10) and dotted grey lines malaria-naive control subjects (n = 4). Values shown as
17.5 on the log-scale were negative (i.e. half the detection limit of the qPCR: 35 parasites/ml).
doi:10.1371/journal.pone.0112910.g004
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and CPS-MQ immunization regimens appear to be reasonably
well tolerated and safe. In 2013, however, after completion of
this study, the U.S. Food and Drug Administration (FDA) issued
a boxed warning for mefloquine, stating that neurologic side
effects might be permanent. This might lead to adjustment of
prophylaxis guidelines and limitation of mefloquine use where
Figure 5. Antibody responses induced by CPS-CQ and CPS-MQ immunization. Antibodies against CSP (A and B; in AU), LSA-1 (C and D),
and MSP-1 (E and F) were analyzed at baseline (B), 28 days after the first (I1) and second (I2) immunization and one day before challenge (C-1; 20
weeks after the last immunization) for all CPS-CQ (A, C and E, n = 5) and CPS-MQ (B, D and F, n = 10) immunized volunteers. Data are shown as
individual titers with medians. Open squares indicate protected subjects, filled circles indicate unprotected subjects. Differences between the time
points were analyzed by Friedman test with Dunn’s multiple comparison post-hoc test. Significant differences are indicated by asterices with * (p,
0.05), ** (p,0.01), *** (p,0.001).
doi:10.1371/journal.pone.0112910.g005
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alternatives are available, as for now it remains a recommended
antimalarial prophylactic for several target groups [31].
In previous studies we showed that 19/20 subjects (95%) were
protected after bites from 45 infected mosquitoes, 8/9 (89%) after
bites from 30 and 5/10 (50%) after bites from 15 infected
mosquitoes during chloroquine prophylaxis [6,7,9]. The 60–70%
protection observed in the current CPS-CQ and CPQ-MQ
groups, immunized with bites from 24 mosquitoes, demonstrates
the reproducibility of CPS immunization and indicates a linear
relationship between immunization dose and protection. This
confirms the consistency of the CPS approach and is remarkable,
given the assumed variation in the number of sporozoites injected
by mosquitoes [32]. This study further establishes CPS immuni-
zation as a worthwhile immunization protocol to relatively easily
induce protection and create differentially protected cohorts to
study target antigens and correlates of protection, both of which
would be highly valuable tools in the search for P. falciparum
vaccines and biomarkers of protection [33].
Although the study was not powered to detect these differences,
there are hints suggestive of more efficient induction of protection
by CPS-CQ compared to CPS-MQ: i) the two unprotected CPS-
CQ volunteers showed a longer prepatent period than the CPS-
MQ subjects (14 versus 12 days, Mann-Whitney test p = 0.13); ii)
induction of immunity required less immunizations in the CPS-
CQ group i.e. none of these subjects showed blood-stage parasites
after the second immunization while subjects in the CPS-MQ
group still developed parasitemia after the second and third
immunization. If there is a difference between CPS-CQ and CPS-
Figure 6. Cellular immune responses: CD107a expression by CD4 T cells and granzyme B production by CD8 T cells. CD107a
expression by CD4 T cells after PfRBC re-stimulation, corrected for uRBC background in CPS-CQ (A) and CPS-MQ (B) groups; granzyme B production by
CD8 T cells after PfRBC re-stimulation, corrected for uRBC background in CPS-CQ (C) and CPS-MQ (D) groups. Symbols and lines represent individual
subjects before immunization (B) and one day before challenge (C-1). Open squares indicate protected subjects, filled circles indicate unprotected
subjects. Differences between B and C-1 for all subjects were tested by Wilcoxon matched-pairs signed rank test.
doi:10.1371/journal.pone.0112910.g006
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MQ in protective efficacy, it is small, but possibly detectable in
larger cohorts or when the immunization dose is further reduced.
Induction of anti-circumsporozoite antibodies by CPS-CQ is
consistent with previous work, but neither anti-LSA-1, nor MSP-1
antibodies were induced by CPS-CQ in the current study [17].
Antibodies against the latter antigens are dose-dependently
induced [17], and the current immunization regime using bites
from 368 P. falciparum-infected mosquitoes might have been
insufficient [7]. The induction of cellular P. falciparum-specific
memory responses, as reflected by IFNc production, is in line with
previous CPS-CQ studies, even though limited sample size
hampered statistical significance for some cell types. Interestingly,
CD107a expression by CD4 T cells upon in vitro re-stimulation,
associated with protection in a previous CPS-CQ study [7],
appeared again to be associated with protection in the CPS-CQ
group, but not the CPS-MQ group. Granzyme B production by
CD8 T cells upon in vitro re-stimulation did not appear to be a
reproducible marker of protection in this second CPS study [7].
Whether this might be related to immunization dose remains to be
investigated in future CPS trials.
The striking efficiency of CPS immunization might at least be
partly due to the established immune modulating properties of the
4-amino-quinoline chloroquine [12], possibly reflected by the
more efficient induction of degranulating CD4 T cells. Chloro-
quine has been shown to increase cross-presentation in hepatitis B
vaccination and influenza [13,14], and thus may enhance cellular
immune responses considered essential for protection against liver-
stages [12]. For mefloquine, a 4-methanolquinoline, this immune-
modulating property has, to our knowledge, not been reported. A
possible strategy to assess whether chloroquine and/or mefloquine
indeed have immune enhancing effects on whole sporozoite
immunization would be to compare immunization with RAS in
the presence or absence of these drugs.
Mefloquine or chloroquine plasma concentrations were still
detectable in all volunteers one day before the challenge infection.
Possible contributing effects of these remaining drug levels to the
protective efficacy outcome were considered in several ways; i)
The interval between first qPCR and thick smear positivity, as
proxy for parasite multiplication, was 2.8 in the CPS-CQ group,
2.0 in the CPS-MQ group and 2.5 in the control group. This
interval is similar to previous CHMI studies with the NF54 P.
falciparum strain in the absence of prophylactic drug levels [7,34];
ii) the two volunteers with the highest mefloquine levels (116 and
77 mg/L) were control subjects who became thick smear positive
with only a minimal delay in patency within the time-frame of
historical controls [35]; iii) plasma chloroquine and mefloquine
levels at C-1 were in all volunteers well below the minimum
therapeutic concentration (CQ: 30 mg/L [36]) or the concentra-
tion at which breakthrough infections are observed in non-
immune people (MQ,406–603 mg/L [37]). iv) We cannot rule
out that protected subjects experienced transient parasitemia after
challenge, which was cleared in the first blood-stage cycle by
remaining drug levels. But because parasitemia was not detected
by qPCR in any of the protected subjects at any time point after
challenge potential parasitemia must have been below the qPCR
detection limit of 35 parasites/ml, indicating a reduction of at least
92% in liver load, given a geometric mean height of the first peak
or parasitemia in non-immune historical controls of 456 parasites/
ml [35]; v) None of the protected subjects showed a boost in anti-
MSP-1 antibodies after challenge while all unprotected subjects
did, suggesting that protected subjects did not experience blood-
stage parasitemia after challenge. [9]. From these combined data
we believe that remaining drug concentrations are unlikely to have
contributed to the observed protection, although this cannot be
formally excluded.
A review of rodent studies using different attenuation methods
for whole sporozoite immunization shows that increased develop-
ment of the parasite in the liver, but absence of blood-stage
parasitemia during immunization is associated with the highest
protective efficacy [38]. It would therefore be interesting to
investigate CPS immunization with alternative antimalarials with
varying targets in the parasite life cycle. CPS immunization with
causal prophylactic drugs affecting liver-stages, e.g. primaquine,
will likely results in a reduction of AEs because of reduced or
absent blood-stage exposure. Whether antigen-exposure is suffi-
cient to induce protection when the liver-stage is abrogated,
remains to be answered.
In conclusion, we show that immunization of healthy volunteers
under mefloquine prophylaxis with P. falciparum sporozoites is
safe, immunogenic and protective. These findings could have
important implications for malaria vaccine development and
further development of CPS approaches.
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